[225Ac]Ac-AKY-1189
- Urothelial Cancer
- Breast Cancer
- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Cervical Cancer
- Undisclosed indication
Aktis Oncology, Inc.
Most recent annual filing: 2026-03-15
Pipeline (9 active programs)
[225Ac]Ac-AKY-2519
AKY-2519- Prostate Cancer
- Non-Small Cell Lung Cancer
- Undisclosed indication
Technology platforms
miniprotein radioconjugate platform · Eli Lilly
Proprietary miniprotein radioconjugate platform using polypeptides of 40-70 amino acids to selectively deliver alpha- or beta-emitting radioisotopes to solid tumors with high tumor penetration, prolonged retention, and rapid clearance from normal tissues. Leverages yeast surface display, AI/generative AI, and medicinal chemistry for discovery. Collaboration with Eli Lilly to generate novel anticancer radiopharmaceuticals against additional targets beyond the company's unpartnered pipeline.
miniprotein radioconjugate platform · Eli Lilly and Company
Isotope-agnostic miniprotein radioconjugate platform designed to selectively deliver radioisotopes to targeted tumors; enables high tumor penetration, internalization and retention in cancer cells with rapid clearance from normal tissues; supports both therapeutic and imaging isotopes across solid tumor indications
Biotech Distilled coverage (3)
- 2026-05-21 UPDATE: Aktis Oncology (AKTS) - The Canary Sings 🔒 Paid
- 2026-05-12 UPDATE: Aktis Oncology (AKTS) - Fast Track, ASCO Date, and the Clock Starts on the Mid-2026 De-risker 🔒 Paid
- 2026-04-30 Aktis Oncology (AKTS) - Scientific Deep Dive for AKY1189 and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.